Specimen Processing Sample Clauses
The Specimen Processing clause outlines the procedures and standards for handling, preparing, and analyzing biological or other types of specimens within the scope of an agreement. It typically details the responsibilities of each party regarding the collection, labeling, storage, transportation, and testing of specimens, ensuring that all steps comply with regulatory and quality requirements. By clearly defining these processes, the clause helps prevent mishandling, ensures the integrity of specimens, and allocates responsibility, thereby reducing the risk of errors and disputes.
Specimen Processing. Laboratory personnel will normally process urine specimens (sample A) by grouping them into batches. When conducting the screening test, every batch shall contain an appropriate number of standards for calibrating the instrumentation and a minimum of 10 percent controls. Current NIDA/SAMHSA standards in affect at the time of collection, and, for those drugs without a NIDA/SAMHSA standard, Attachment "C" shall be used for the immunoassay screening test which will be used to eliminate "negative" urine samples from further consideration. Detailed screening and quality assurance procedures are discussed in the Laboratory Procedural Manual. Written documentation shall be maintained by the laboratory showing details of all the EMIT screening tests done under this program. These data may be reviewed by consultants to the Union. All samples that initially screen positive shall be stored in the locked employee Drug Testing freezer in the Toxicology Section until conformation studies by GC/MS are complete.
Specimen Processing. Laboratory personnel will normally process urine specimens (sample A) by grouping them into batches. When conducting the screening test, every batch shall contain an appropriate number of standards for calibrating the instrumentation and a minimum of 10 percent controls. Current /SAMHSA standards in affect at the time of collection, and, for those drugs without a /SAMHSA standard, Attachment "C" shall be used for the immunoassay screening test which will be used to eliminate "negative" urine samples from further consideration. Detailed screening and quality assurance procedures are discussed in the Laboratory Procedural Manual. Written documentation shall be maintained by the laboratory showing details of all the screening tests done under this program. These data may be reviewed by consultants to the Union. All samples that initially screen positive shall be stored in the locked employee Drug Testing freezer in the Toxicology Section until conformation tests are complete.
Specimen Processing. For Motorola BioChip customers, GMP|Genetics shall, during the Exclusivity Period, process specimens in accordance with its standard procedures and standard terms and conditions. GMP|Genetics shall charge such customers the lower of:
(A) the then current list price for processing requested for commercial purposes (i.e. outside the Research Field), or (B) the price charged for similar specimen processing for commercial purposes. The initial price list is attached hereto as Exhibit C and may be updated periodically by GMP|Genetics. For each specimen submitted to GMP|Genetics that is identified for the Commercial Field using BioChips, GMP|Genetics shall use all reasonable efforts to immediately initiate the processing for such specimens, which in no event shall be any different from the processing received by other GMP|Genetics customers.
Specimen Processing. When conducting tests, every batch of specimens is required to have an appropriate number of standards for calibrating instruments and a minimum of 10 percent controls. Both quality control and blind performance test samples are required to appear as ordinary samples to laboratory analysts.